Background. Bacteremia due to Entrobacteriaceae gram-negative rods (GNR) can be life threatening. Appropriate antimicrobial therapy is critical to reduce morbidity and mortality.
Methods. A retrospective cohort study (2008) (2009) (2010) (2011) was conducted in children and young adults (<21 years of age) hospitalized with Entrobacteriaceae bacteremia with clinical signs and symptoms. We assessed if combination antimicrobial therapy is superior to monotherapy in treatment of Klebsiella, Ecoli or Enterobacter bacteremia. Monotherapy was defined as empirical therapy with β lactam alone, and combination therapy as β lactam with aminoglycoside for at least 48 hrs. Multi drug resistant (MDR) GNR were defined as those organisms resistant to at least one agent in three or more antimicrobial categories. Clinical outcome was measured as response to therapy and 7-and 30-day mortality. Response to therapy, defined as time to negative blood culture, was compared among patients given monotherapy vs combination therapy.
Results. Of 289 episodes of Entrobacteriaceae GNR bacteremia, 79 (27%) were due to Klebsiella species, of which 11 (14%) were MDR; 73 (25%) due to Escherichia coli, of which 11 (15%) were MDR; and 53 (18%) due to Enterobacter, of which 13 (25%) were MDR, 48 (16%) were Salmonella, Citrobacter and others. Of the 203 episodes of bacteremia caused by the three organisms of interest, 101 (50%) were treated with combination therapy. Patients with cancer were more likely to receive combination therapy ( p < 0.001), while patients with gastrointestinal disease and those receiving total parenteral nutrition were more likely to receive monotherapy ( p = 0.006 and p = 0.013, respectively). There were no differences in time to negative blood culture based on treatment group, organism or resistance pattern. The mean time to negative blood culture was 3 days (SD = 1.1 days). There was no significant difference in 7-and 30-day mortality between monotherapy and combination therapy group.
Conclusion. Combination therapy consisting of β lactam and aminoglycoside was not superior to mono-therapy with β lactam alone for managing Entrobacteriaceae GNR bacteremia in children and young adults.
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